ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY): 40 pipeline candidates · 3 upcoming catalysts · ~14 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.7 months
D/E 3.69 · 0% dilution
Lead: Phase 3
40 candidates
3 upcoming, next in ~501d
N/A
A transparent, data-derived signal for ARS Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$983.1M
Cash
$24.3M
Quarterly Burn
$44.9M
Runway
13.7 mo
Revenue
$22.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (40 candidates)
| Drug | Phase |
|---|---|
| Abiraterone Acetate | Phase 3 |
| adrenaline | Phase 4 |
| ADX-038 | Phase 2 |
| ADX-038 Dose Level 1 | Phase 2 |
| ADX-038 Dose Level 2 | Phase 2 |
| ALXN1920 | Phase 2 |
| ALXN2030 | Phase 2 |
| Antiandrogen Therapy | Phase 2 |
| Apalutamide | Phase 3 |
| ars-1 | Phase 2 |
Showing 10 of 40 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
200
Total value held
$626.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 10,860,977 | $87.2M |
| orbimed advisors llc | 8,288,510 | $66.6M |
| deerfield management company, l.p. | 7,503,812 | $60.3M |
| millennium management llc | 5,982,919 | $48.0M |
| vanguard capital management llc | 5,085,008 | $40.8M |
| blackrock, inc. | 5,012,254 | $40.2M |
| state street corp | 3,644,966 | $29.3M |
| franklin resources inc | 3,278,549 | $26.3M |
| tyro capital management llc | 2,968,599 | $23.8M |
| ubs group ag | 2,260,325 | $18.2M |
Showing top 10 of 200 institutional holders of ARS Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARS Pharmaceuticals, Inc.'s pipeline?
ARS Pharmaceuticals, Inc. (SPRY) has 40 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARS Pharmaceuticals, Inc.'s lead drug candidate?
ARS Pharmaceuticals, Inc.'s most advanced tracked candidate is Abiraterone Acetate (Phase 3) for Prostatic Neoplasms; Castration-Resistant Prostate Carcinoma; Prostate Carcinoma.
What is ARS Pharmaceuticals, Inc.'s next catalyst?
ARS Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abirat" — expected November 1, 2027.
What is ARS Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARS Pharmaceuticals, Inc. has approximately 13.7 months of cash runway.
What is ARS Pharmaceuticals, Inc.'s market capitalization?
ARS Pharmaceuticals, Inc.'s market capitalization is approximately $983.1M.
Get the full picture on ARS Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.